[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100583939":3},{"organization":4,"armGroups":7,"interventions":10,"overallOfficials":12,"centralContacts":17,"locations":28,"responsibleParty":46,"collaborators":10,"id":49,"slug":50,"hasResults":51,"nctId":52,"briefTitle":53,"officialTitle":54,"acronym":10,"eligibilityCriteria":55,"healthyVolunteers":56,"sex":57,"minAge":58,"maxAge":10,"enrollmentInfo":59,"targetDuration":62,"studyType":63,"phases":10,"briefSummary":64,"conditions":65,"keywords":69,"overallStatus":31,"whyStopped":10,"lastUpdateSubmitDate":73,"lastUpdatePostDateStruct":74,"startDateStruct":77,"completionDateStruct":79,"leadSponsor":81,"locationsCount":82},{"fullName":5,"class":6},"Unidade Local de Saúde de Coimbra, EPE","OTHER",[8],{"label":9,"type":10,"description":11,"interventionNames":10},"Healthy pregnancies",null,"High-risk preeclampsia pregnencies",[13],{"name":14,"affiliation":15,"role":16},"Ana L Areia, PhD MD","University of Coimbra","PRINCIPAL_INVESTIGATOR",[18,23],{"name":19,"role":20,"phone":21,"phoneExt":10,"email":22},"Ana L Areia, PhD, MD","CONTACT","+351917212222","analuisareia@gmail.com",{"name":24,"role":20,"phone":25,"phoneExt":26,"email":27},"João Sargento-Freitas, PhD","+351239400488","12105","joaosargentofreitas@ulscoimbra.min-saude.pt",[29],{"facility":30,"status":31,"city":32,"state":33,"zip":34,"country":35,"countryCode":36,"cosmosGeoPoint":37,"geoPoint":42,"contacts":43},"Unidade Local de Saúde de Coimbra, E.P.E.","RECRUITING","Coimbra","Coimbra District","3000-075","Portugal","PT",{"type":38,"coordinates":39},"Point",[40,41],-8.41996,40.20686,{"lat":41,"lon":40},[44],{"name":45,"role":20,"phone":21,"phoneExt":10,"email":22},"Ana Areia, PhD, MD",{"type":16,"investigatorFullName":47,"investigatorTitle":48,"investigatorAffiliation":5,"oldNameTitle":10,"oldOrganization":10},"Ana Luisa Areia","Clinical Professor","100583939","immunomodulation-during-pregnancy-100583939",false,"NCT06882850","Immunomodulation During Pregnancy","Immunomodulation During Pregnancy Through Low-Dose Aspirin: a Hypothetical Mechanism for the Prevention of Preeclampsia?","Inclusion Criteria: - Singleton pregnancy\n\n* Patients attending prenatal consultations at the Obstetrics Service A of CHUC, with the first consultation occurring before 14 weeks of gestation\n* Gestational age determined by first-trimester ultrasound\n* Study group: Women classified as high risk for PE according to clinical\u002Fhistorical criteria and the Fetal Medicine Foundation algorithm. LDA-naïve.\n\nExclusion Criteria: Multiple pregnancy\n\n* Autoimmune diseases\n* Prior use of LDA or other immunomodulatory medication before potential recruitment\n* History of spontaneous miscarriages and\u002For medical termination of pregnancy\n* Fetal malformation",true,"FEMALE","18 Years",{"count":60,"type":61},30,"ESTIMATED","30 Weeks","OBSERVATIONAL","The goal of this observational study is to learn about the effects of low dose aspirin in immunity Pregnant women taking aspirin for other reasons (preeclampsia prevention) will be studied. The main question it aims to answer is: evaluate the effect of LDA on the modulation of innate immunity cells (NK cells, monocytes, γδ T cells) and\u002For acquired immunity (B and T lymphocytes, Treg cells, Th cells).\n\nParticipants already taking intervention A as part of their regular medical care for RA will answer online survey questions about their joint pain for 5 years.",[66,67,68],"Aspirin","Pregnancy Complications","Immunology",[68,70,66,71,72],"Pregnancy","Lymphocytes","T-Lymphocytes","2025-03-15",{"date":75,"type":76},"2025-03-19","ACTUAL",{"date":78,"type":76},"2024-02-01",{"date":80,"type":61},"2025-03-31",{"name":5,"class":6},1]